NACDS Applauds Rejection of California State Legislation That Would Disempower Patients, Drive Up Healthcare Costs

Published Online: Friday, January 13, 2012
The National Association of Chain Drug Stores (NACDS) applauded the rejection of California legislation that would require a prescription for over-the-counter products containing pseudoephedrine, a key ingredient in cold and allergy medications.
 
This anti-consumer legislation (SB 315) would have mandated prescriptions for pseudoephedrine-containing products, thereby skyrocketing healthcare costs and reducing Californians’ access to health care, while not reducing the drug abuse and misuse of these products

NACDS joined state partners in California to oppose this legislation.  The Association testified before state lawmakers, highlighting community pharmacy’s commitment to working with law enforcement to help provide them access to the information they need to identify and stop this criminal activity, while ensuring patients have access to the over-the-counter medications that they rely on to treat illnesses.
 
NACDS also stressed that the prescription requirement would result in increased healthcare costs, resulting from an increase in doctors’ visits, prescription pharmacy costs, Medi-Cal costs and insurance premiums.
 
“We are pleased that California lawmakers rejected this anti-consumer legislation.  Requiring a prescription for over-the-counter products containing pseudoephedrine would be a cure worse than the disease,” said NACDS President and CEO Steven C. Anderson, IOM, CAE.  “A prescription requirement would disempower patients in their own healthcare and would only increase healthcare costs."

NACDS continues working with state and federal officials to curb pseudoephedrine misuse and abuse, emphasizing that a prescription-only approach would have detrimental impacts on patients and the healthcare system.
Latest Articles
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Vertex Pharmaceuticals has received a complete response letter from the FDA for its supplemental new drug application for ivacaftor.
Latest Issues
$auto_registration$